The differential magnitude of mTOR suppression between BCc1 and cyclophosphamide also provides a mechanistic rationale for combination regimens, potentially enabling synergistic inhibition of tumor growth while mitigating adaptive resistance. This evidence concerns the gene MTOR and neoplasm.